Full name
WASILEWICZ EYE INSTITUTE SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
72.19.Z - Other research and experimental development on natural sciences and engineering
21.10.Z - Manufacture of basic pharmaceutical substances
21.20.Z - Manufacture of medicines and other pharmaceutical products
58.19.Z - Other publishing activities
82.30.Z - Organisation of conventions and trade shows
85.59.B - Other out-of-school forms of education, not elsewhere classified
85.60.Z - Educational support activities
86.22.Z - Specialist medical practice activities
86.90.E - Other human health activities notelsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Gross profit (loss) | 12,9 | 3,4 | -41,3 | -1307,3 |
EBITDA | 12,9 | 3,4 | -41,3 | -1307,3 |
Short time liabilities | 1,2 | 0,5 | 9,6 | 1747,7 |
Equity capital | 16,7 | 19,8 | -21,5 | -208,5 |
Operating profit (EBIT) | 12,9 | 3,4 | -41,3 | -1307,3 |
Assets | 17,9 | 22,8 | 1,2 | -94,5 |
Net profit (loss) | 11,7 | 3,1 | -41,3 | -1426,7 |
Cash | 17,9 | 22,8 | 1,2 | -94,5 |
Net income from sale | 45 | 30 | 0 | -100 |
Liabilities and provisions for liabilities | 1,2 | 3 | 22,7 | 652,6 |
Working assets | 17,9 | 22,8 | 1,2 | -94,5 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | 70,1 | 15,7 | 192,1 | 176,4 |
Equity capital to total assets | 93,5 | 86,8 | -1725,3 | -1812,1 |
Gross profit margin | 28,6 | 11,4 | -17,2 | |
EBITDA Margin | 28,6 | 11,4 | -17,2 | |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 9 | 6 | 2 147 483 648 | 2 147 483 642 |
Current financial liquidity indicator | 15.429558753967285 | 43.736515045166016 | 0.12919673323631287 | -43,6 |
Net dept to EBITDA | -1.3890445232391357 | -5.942042827606201 | -0.2869683802127838 | 5,6 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane